Supplemental Table S1. Patient's characteristics at diagnosis of *de novo* AML (n = 39)

Median age	58 [24 ; 88]
Sex ratio (M/W)	2
Leukocytosis	**n (%)**
< 4 $10^3/\mu L$	8 (20)
4-30 $10^3/\mu L$	17 (44)
30-100 $10^3/\mu L$	11 (28)
> 100 $10^3/\mu L$	3 (8)
AML subtype (FAB classification)	**n (%)**
M0	2 (5)
M1	9 (23)
M2	18 (46)
M4	6 (16)
M5	4 (10)
Bone marrow blasts	**n (%)**
20-40%	9 (23)
40-60%	11 (28)
60-80%	9 (23)
80-100%	10 (26)
Prognosis (ELN 2017)	**n (%)**
Favorable	21 (54)
Adverse	18 (46)
Molecular status	**n (%)**
NPM1	15 (38)
FLT3-ITD	11 (28)
IDH	9 (23)
TET2	4 (10)
CEBPA	4 (10)
RUNX1	1 (3)
TP53	1 (3)
Response to chemotherapy	**n (%)**
Chemosensitive	20 (51)
Chemoresistant	6 (16)
Non available	13 (33)